Company Overview: Intec Pharma

Industry News

10 Jul

Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer

JERUSALEM, July 10, 2017 /PRNewswire/ — Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A. Meckler as Chief Executive Officer, effective immediately. Mr. Meckler was named Vice Chairman of the Intec Pharma...

Read more

14 Mar

Intec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results

JERUSALEM, ISRAEL–(Marketwired – Mar 14, 2016) – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the year ended December 31, 2015 and provided a business update. Results are...

Read more

14 Mar

Intec Pharma Ltd.: Notice of Special General Meeting of Shareholders

JERUSALEM, ISRAEL–(Marketwired – Mar 14, 2016) – Notice is hereby given that the special general meeting of shareholders of Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) (the “Company“), will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., One Azrieli Center, Round Building, Tel Aviv 6701101, Israel...

Read more

10 Mar

Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product

JERUSALEM, ISRAEL–(Marketwired – Mar 10, 2016) –  Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with its third pipeline product. The product is being developed...

Read more

5 Jan

Intec Pharma to Present at Biotech Showcase 2016

JERUSALEM, ISRAEL–(Marketwired – Jan 5, 2016) – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will present at Biotech Showcase on January 13, 2016 at 10:30 a.m....

Read more

14 Dec

Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP – CDLD for the Treatment of Parkinson’s Disease

JERUSALEM, ISRAEL–(Marketwired – Dec 14, 2015) – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized institutional review board (IRB) approval to initiate its Phase III clinical trial...

Read more

8 Dec

Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product

JERUSALEM, ISRAEL–(Marketwired – Dec 8, 2015) – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical trial with its third pipeline product. The product is being developed...

Read more

6 Nov

Intec Pharma Reports Results for the Third Quarter of 2015

JERUSALEM, ISRAEL–(Marketwired – Nov 5, 2015) –   Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) (“Intec Pharma” or the “Company”), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the third quarter ended September 30, 2015 and...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address